• Atsuya Takeda, Naoko Sanuki, Takahisa Eriguchi, Takeshi Kaneko, Satoshi Morita, Hiroshi Handa, Yousuke Aoki, Yohei Oku, and Etsuo Kunieda.
• Radiation Oncology Center, Ofuna Chuo Hospital, Kanagawa, Japan.
• Int. J. Radiat. Oncol. Biol. Phys. 2013 Jun 1;86(2):257-63.

PurposeTo retrospectively investigate treatment outcomes of stereotactic ablative body radiation therapy (SABR) for octogenarians with non-small cell lung cancer (NSCLC).Methods And MaterialsBetween 2005 and 2012, 109 patients aged ≥80 years with T1-2N0M0 NSCLC were treated with SABR: 47 patients had histology-unproven lung cancer; 62 patients had pathologically proven NSCLC. The prescribed doses were either 50 Gy/5 fractions for peripheral tumors or 40 Gy/5 fractions for centrally located tumors. The treatment outcomes, toxicities, and the correlating factors for overall survival (OS) were evaluated.ResultsThe median follow-up duration after SABR was 24.2 (range, 3.0-64.6) months. Only limited toxicities were observed, except for 1 grade 5 radiation pneumonitis. The 3-year local, regional, and distant metastasis-free survival rates were 82.3%, 90.1%, and 76.8%, respectively. The OS and lung cancer-specific survival rates were 53.7% and 70.8%, respectively. Multivariate analysis revealed that medically inoperable, low body mass index, high T stage, and high C-reactive protein were the predictors for short OS. The OS for the operable octogenarians was significantly better than that for inoperable (P<.01).ConclusionsStereotactic ablative body radiation therapy for octogenarians was feasible, with excellent OS. Multivariate analysis revealed that operability was one of the predictors for OS. For medically operable octogenarians with early-stage NSCLC, SABR should be prospectively compared with resection.Copyright © 2013 Elsevier Inc. All rights reserved.

27 keywords...

hide…